Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis

Molecular Cancer Therapeutics

Volumn 8, Issue 9, 2009, Pages 2708-2717

  Carriero, Maria Vincenza ^a   Longanesi Cattani, Immacolata ^a   Bifulco, Katia ^a   Maglio, Ornella ^c,d   Lista, Liliana ^c   Barbieri, Antonio ^a   Votta, Giuseppina ^e   Masucci, Maria Teresa ^a   Arra, Claudio ^a   Franco, Renato ^b   De Rosa, Mario ^f   Stoppelli, Maria Patrizia ^e   Pavone, Vincenzo ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d CNR   (Italy)

^e INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE; ARGINYLGLUTAMYLARGINYLPHENYLALANINAMIDE; CD51 ANTIGEN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; FORMYLPEPTIDE RECEPTOR; GREEN FLUORESCENT PROTEIN; MATRIGEL; PLASMINOGEN ACTIVATOR INHIBITOR; SERINE; TYROSINE; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; FEMALE; FIBROSARCOMA; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERNALIZATION; LEUKEMIA CELL; LUNG METASTASIS; MAST CELL LEUKEMIA; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RAT; STRUCTURE ACTIVITY RELATION; TUMOR VOLUME; WOUND CLOSURE; WOUND HEALING IMPAIRMENT;

ANIMALS; CELL MOVEMENT; FEMALE; FIBROSARCOMA; HUMANS; IMMUNOPRECIPITATION; LUNG NEOPLASMS; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; MODELS, MOLECULAR; NEOPLASM METASTASIS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; RATS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 70349484458     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0174     Document Type: Article

References (44)

1. Blasi F, Carmeliet P. uPAR: a versatile signaling orchestrator. Nat Rev Mol Cell Biol 2002;3:932-943 (Pubitemid 35477371)
2. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000;12:613-620 (Pubitemid 30702157)
3. Jacobsen B, Ploug M. The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition. Curr Med Chem 2008;15:2559-2573
4. Alfano D, Franco P, Vocca I, et al. The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis. Thromb Haemost 2005;93:205-211 (Pubitemid 40253723)
5. Del Vecchio S, Stoppelli MP, Carriero MV, et al. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 1993;53:3198-3206 (Pubitemid 23210335)
6. Dano K, Behrendt N, Hoyer-Hansen G, et al. Plasminogen activation and cancer. Thromb Haemost 2005;93:676-681
7. Romer J, Nielsen BS, Ploug M. The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des 2004;10:2359-2376 (Pubitemid 38855042)
8. Pillay V, Dass CR, Choong PF. The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 2007;25:33-39 (Pubitemid 46001467)
9. Degryse B, Resnati M, Czekay RP, Loskutoff DJ, Blasi F. Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor. J Biol Chem 2005;280:24792-24803 (Pubitemid 40934570)
10. Sato S, Kopitz C, Schmalix WA, et al. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett 2002;528:212-216 (Pubitemid 35258026)
11. Rasch MG, Lund IK, Almasi CE, Hoyer-Hansen G. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front Biosci 2008;13:6752-6762
12. Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem 2002;277:46932-46939 (Pubitemid 36159197)
13. Gargiulo L, Longanesi-Cattani I, Bifulco K, et al. Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide. J Biol Chem 2005;280:25225-25232 (Pubitemid 40934616)
14. Resnati M, Pallavicini I, Wang JM, et al. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci U S A 2002;99:1359-1364 (Pubitemid 34136498)
15. Carriero MV, Del Vecchio S, Capozzoli M, et al. Urokinase receptor interacts with α(v)β5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 1999;59:5307-5314
16. Kugler MC, Wei Y, Chapman HA. Urokinase receptor and integrin interactions. Curr Pharm Des 2003;9:1565-1574
17. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003;22:205-222 (Pubitemid 36561058)
18. Llinas P, Le Du MH, Gårdsvoll H, et al. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J 2005;24:1655-1663 (Pubitemid 40704976)
19. Huai Q, Mazar AP, Kuo A, et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science 2006;311:656-659 (Pubitemid 43191309)
20. Barinka C, Parry G, Callahan J, et al. Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol 2006;363:482-495 (Pubitemid 44472493)
21. Gårdsvoll H, Ploug M. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. J Biol Chem 2007;282:13561-13572 (Pubitemid 47100512)
22. Huai Q, Zhou A, Lin L, et al. Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat Struct Mol Biol 2008;15:422-423
23. Bifulco K, Longanesi-Cattani I, Gargiulo L, et al. An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor. FEBS Lett 2008;582:1141-1146
24. Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res 2000;28:235-242
25. Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 1990;35:161-214. (Pubitemid 20126875)
26. Franco P, Vocca I, Carriero MV, et al. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and (α)v(β)5 integrin. J Cell Sci 2006;119:3424-3434 (Pubitemid 44405226)
27. Hall AL, Wilson BS, Pfeiffer JR, Oliver JM, Sklar LA. Relationship of ligand-receptor dynamics to actin polymerization in RBL-2H3 cells transfected with the human formyl peptide receptor. J Leukoc Biol 1997;62:535-546
28. Silvestri I, Longanesi-Cattani I, Franco P, et al. Engaged urokinase receptors enhance tumor breast cell migration and invasion by up-regulating αvβ5 vitronectin receptor cell surface expression. Int J Cancer 2002;102:562-571 (Pubitemid 35334462)
29. Carriero MV, Del Vecchio S, Franco P, et al. Vitronectin binding to urokinase receptor in human breast cancer. Clin Cancer Res 1997;3:1299-1308 (Pubitemid 27362390)
30. Bennett TA, Maestas DC, Prossnitz ER. Arrestin binding to the G protein-coupled N-formyl peptide receptor is regulated by the conserved "DRY" sequence. J Biol Chem 2000;275:24590-24594
31. Weiss JN. The Hill equation revisited: uses and misuses. FASEB J 1997;11:835-841
32. Baroni A, Donnarumma G, Paoletti I, et al. Antimicrobial human β-defensin-2 stimulates migration, proliferation and tube formation of human umbilical vein endothelial cells. Peptides 2009;30:267-272
33. Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 1983;22:2577-2637
34. Pavone V, Gaeta G, Lombardi A, et al. Discovering protein secondary structures: classification and description of isolated α-turns. Biopolymers 1996;38:705-721 (Pubitemid 26147647)
35. Ramakrishnan C, Nataraj DV. Energy minimization studies on α-turns. J Pept Sci 1998;4:239-252
36. Perez DM, Karnik SS. Multiple signaling states of G-protein-coupled receptors. Pharmacol Rev 2005;57:147-161
37. Yamamoto N, Jiang P, Yang M, et al. Cellular dynamics visualized in live cells in vitro and in vivo by differential dual-color nuclear-cytoplasmic fluorescent-protein expression. Cancer Res 2004;64:4251-4256 (Pubitemid 38802430)
38. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25:9-34.
39. Miettinen HM, Mills JS, Gripentrog JM, Dratz EA, Granger BL, Jesaitis AJ. The ligand binding site of the formyl peptide receptor maps in the transmembrane region. J Immunol 1997;159:4045-4054
40. Vocca I, Franco P, Alfano D, et al. Inhibition of migration and invasion of carcinoma cells by urokinase-derived antagonists of αvβ5 integrin activation. Int J Cancer 2009;124:316-325
41. Yuan C, Huang M. Does the urokinase receptor exist in a latent form? Cell Mol Life Sci 2007;64:1033-1037
42. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007;7:79-94.
43. Huang J, Chen K, Gong W, et al. Receptor "hijacking" by malignant glioma cells: a tactic for tumor progression. Cancer Lett 2008;267:254-261
44. Yan P, Nanamori M, Sun M, et al. The immunosuppressant cyclosporin A antagonizes human formyl peptide receptor through inhibition of cognate ligand binding. J Immunol 2006;177:7050-7058 (Pubitemid 44715072)